Who Paid My Doc
Marte Martinez
Pain Medicine Laredo, TX Medical Doctor
NPI 1467658047 CMS profile 21514
7614 Rocio Dr, Laredo, TX 78041
General payments
$9,320
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$123,635
Through program year 2025, Marte Martinez of Laredo, TX is reported in the CMS Open Payments database as having received $9,320 across 126 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $123,635 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 79th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,369 | 31 | |
| 2024 | General | $827 | 17 | |
| 2023 | General | $201 | 8 | |
| 2022 | General | $284 | 13 | |
| 2021 | General | $3,181 | 19 | |
| 2020 | General | $436 | 5 | |
| 2019 | General | $3,021 | 33 |
Beside peers
- Marte Martinez
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Marte Martinez were reported at $1,369. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.
Show as a table
| Year | Marte Martinez | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,021 | $498 | $126–$1,682 | $163 |
| 2020 | $436 | $284 | $80–$910 | $114 |
| 2021 | $3,181 | $399 | $112–$1,219 | $132 |
| 2022 | $284 | $455 | $137–$1,484 | $149 |
| 2023 | $201 | $484 | $128–$1,495 | $160 |
| 2024 | $827 | $498 | $131–$1,540 | $164 |
| 2025 | $1,369 | $458 | $124–$1,401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 38 drugsPart D claims
6,242
Drug cost
$224,333
Branded share of claims
35.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tymlos Abaloparatide | Brand | 30 | $77,820 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 1,466 | $40,474 | |
| Nucynta Tapentadol Hcl | Brand | 20 | $17,421 | |
| Fentanyl | Generic | 120 | $11,100 | |
| Gabapentin | Generic | 775 | $9,562 | |
| Pregabalin | Generic | 480 | $9,552 | |
| Diclofenac Sodium | Generic | 448 | $6,947 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 201 | $5,950 | |
| Hysingla Er Hydrocodone Bitartrate | Brand | 13 | $5,529 | |
| Hydrocodone Bitartrate Er Hydrocodone Bitartrate | Brand | 19 | $5,120 |
The 10 drugs with the highest cost, of 38 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 87 billing codesPaid by Medicare
$529,468
Medicare patients
505
Services billed
4,552
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 58% | |
| Ischemic heart disease | 39% | |
| Chronic kidney disease | 35% | |
| Depression | 31% | |
| Osteoporosis | 27% | |
| COPD | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 | Office | 21 | 85 | $4,745 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 52 | 62 | $287 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 329 | 758 | $71 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 151 | 238 | $24 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 21 | 27 | $15 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
126 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pain Medicine in Texas
Related records
Pain Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.